The global market for Point of Care (POC) Molecular Diagnostics was valued at US$4.2 Billion in 2024 and is projected to reach US$8.8 Billion by 2030, growing at a CAGR of 12.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Point of Care (POC) Molecular Diagnostics market.
The utility of POC molecular diagnostics has become increasingly evident in healthcare settings around the world, particularly in emergency rooms, intensive care units, and remote areas where access to conventional lab facilities may be limited. In infectious disease management, such as the timely diagnosis of influenza, COVID-19, and other viral infections, POC testing can drastically reduce the spread of infections by enabling quick isolation decisions. Additionally, in settings like oncology, POC molecular diagnostics facilitate the real-time assessment of tumor markers and mutations, which can guide personalized treatment strategies directly at the point of care. The technology's adaptability to non-hospital environments, such as pharmacies and community clinics, further extends its reach and impact, making diagnostic services accessible to a broader population.
The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.
Global Point of Care (POC) Molecular Diagnostics Market - Key Trends and Drivers Summarized
Point of Care (POC) molecular diagnostics involves the performance of molecular diagnostic tests near the site of patient care rather than in a central laboratory. This technology enables the rapid detection of diseases through nucleic acid analysis, providing results within minutes or hours rather than days. The aim is to deliver timely information to healthcare providers, enabling immediate clinical decision-making and treatment initiation. POC molecular diagnostic devices are typically portable or handheld, designed to be easy to use with minimal training, and require fewer operational steps compared to traditional lab-based tests. This rapid and convenient form of testing is particularly valuable for managing infectious diseases, genetic conditions, and cancer, among other medical applications.The utility of POC molecular diagnostics has become increasingly evident in healthcare settings around the world, particularly in emergency rooms, intensive care units, and remote areas where access to conventional lab facilities may be limited. In infectious disease management, such as the timely diagnosis of influenza, COVID-19, and other viral infections, POC testing can drastically reduce the spread of infections by enabling quick isolation decisions. Additionally, in settings like oncology, POC molecular diagnostics facilitate the real-time assessment of tumor markers and mutations, which can guide personalized treatment strategies directly at the point of care. The technology's adaptability to non-hospital environments, such as pharmacies and community clinics, further extends its reach and impact, making diagnostic services accessible to a broader population.
The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.
Report Scope
The report analyzes the Point of Care (POC) Molecular Diagnostics market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.- Segments: Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based); Application (Infectious Diseases, Oncology, Hematology, Other Applications); End-Use (Decentralized Labs, Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses).
- Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Infectious Diseases Application segment, which is expected to reach US$6.2 Billion by 2030 with a CAGR of 12.9%. The Oncology Application segment is also set to grow at 14.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2024, and China, forecasted to grow at an impressive 15.4% CAGR to reach $1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Point of Care (POC) Molecular Diagnostics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Point of Care (POC) Molecular Diagnostics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Point of Care (POC) Molecular Diagnostics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Bayer AG, Danaher Corporation, DiaSorin SpA, Biocartis NV, Maxim Biomedical, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 64 companies featured in this Point of Care (POC) Molecular Diagnostics market report include:
- Bayer AG
- Danaher Corporation
- DiaSorin SpA
- Biocartis NV
- Maxim Biomedical, Inc.
- AccuBioTech Co., Ltd.
- Abacus Diagnostica Oy
- genedrive plc
- Molbio Diagnostics Pvt. Ltd.
- Mesa Biotech, Inc.
- Binx Health
- Credo Diagnostics Biomedical Pte. Ltd
- Genestat Molecular Diagnostics, LLC
- Alveo Technologies
- ADOR Diagnostics
This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Danaher Corporation
- DiaSorin SpA
- Biocartis NV
- Maxim Biomedical, Inc.
- AccuBioTech Co., Ltd.
- Abacus Diagnostica Oy
- genedrive plc
- Molbio Diagnostics Pvt. Ltd.
- Mesa Biotech, Inc.
- Binx Health
- Credo Diagnostics Biomedical Pte. Ltd
- Genestat Molecular Diagnostics, LLC
- Alveo Technologies
- ADOR Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 409 |
| Published | October 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 4.2 Billion |
| Forecasted Market Value ( USD | $ 8.8 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
